Meeting
2019 Breakthrough
Expression of CD47 and CALR in myeloproliferative neoplasms: Potential new therapeutic targets.
Authors
Ciro Roberto Rinaldi
University of Lincoln, Lincoln, United Kingdom
Ciro Roberto Rinaldi , Kristian Boasman , Matthew Simmonds
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Access to Care, Diagnostics, Early Detection and Diagnosis, Prevention and Screening, and Surveillance
Track
Access to Care,Diagnostics,Early Detection and Diagnosis,Prevention and Screening,Surveillance
Sub Track
Early Detection and Diagnosis
Citation
J Glob Oncol 5, 2019 (suppl 1; abstr 48)
DOI
10.1200/JGO.2019.5.suppl.48
Abstract #
48
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Expression of CD47 and CALR in myeloproliferative neoplasms and myelodysplastic syndrome: Potential new therapeutical targets.
First Author: Ciro Roberto Rinaldi
Poster
2024 ASCO Breakthrough
Therapeutically targeting the CALR/CD47 pathway in MPN to reactivate natural immunosurveillance mechanisms within the body to enhance treatment outcomes.
First Author: Ciro Roberto Rinaldi
Poster
2023 ASCO Breakthrough
Effect of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.
First Author: Ciro Roberto Rinaldi
Poster
2023 ASCO Annual Meeting
Effects of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy.
First Author: Ciro Roberto Rinaldi